AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29387874 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS + FCS
Number of subjects: 30
Study 29387874 — intervention group
Group type: COMPARATOR
Intervention: ECS
Number of subjects: 30
Study 26522611 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse kinetic monitoring (TLM)
Number of subjects: 235
Study 26522611 — intervention group
Group type: COMPARATOR
Intervention: Conventional once‐daily morphologic embryo screening (CS)
Number of subjects: 235
Study 26522611 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse kinetic monitoring (TLM) with blastocyst transfers
Number of subjects: 235
Study 26522611 — intervention group
Group type: COMPARATOR
Intervention: Conventional once‐daily morphologic embryo screening (CS) with blastocyst transfers
Number of subjects: 235
Study 25333730 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC) in adults
Number of subjects: 271
Study 25333730 — intervention group
Group type: COMPARATOR
Intervention: Hazelnut allergy in children
Number of subjects: 271
Study 25333730 — intervention group
Group type: COMPARATOR
Intervention: Birch pollen allergy
Number of subjects: 271
Study 25333730 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic parameters
Number of subjects: 271
Study 22878435 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videodisc
Number of subjects: 92
Study 22878435 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 92
Study 20593350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (UPD)
Number of subjects: 27
Study 20593350 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysate (CD)
Number of subjects: 27
Study 18781483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg
Number of subjects: 67
Study 18781483 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 67
Study 18781483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11986538 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with adherence facilitation intervention (n=7)
Number of subjects: 13
Study 11986538 — intervention group
Group type: COMPARATOR
Intervention: Exercise only group (n=6)
Number of subjects: 13
Study 9822087 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (bolus plus infusion)
Number of subjects: 4154
Study 9822087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4154
Study 9822087 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 4154
Study 7950105 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm by 6 mm oval PMMA optic (group I)
Number of subjects: 80
Study 7950105 — intervention group
Group type: COMPARATOR
Intervention: 6 mm diameter round PMMA optic (group II)
Number of subjects: 80
Study 2517111 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite sealant applied after enamel etching using a rubber dam.
Number of subjects: 52
Study 2517111 — intervention group
Group type: COMPARATOR
Intervention: Cermet cement sealings applied without enamel etching after cleaning with pumice powder and sodium hypochlorite.
Number of subjects: 52
Study 790946 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose aspirin (ASA) for 14 days
Number of subjects: 8
Study 790946 — intervention group
Group type: COMPARATOR
Intervention: Interrupted high-dose aspirin (ASA) for 14 days
Number of subjects: 8
Study 31813538 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger RBC units (stored for ≤14 days)
Number of subjects: 1387
Study 31813538 — intervention group
Group type: COMPARATOR
Intervention: Older RBC units (stored for ≥20 days)
Number of subjects: 1387
Study 31587887 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic modified Nissen fundoplication
Number of subjects: 175
Study 31587887 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 80 mg/d, orally
Number of subjects: 175
Study 31587887 — intervention group
Group type: COMPARATOR
Intervention: Observation (no gastroesophageal reflux)
Number of subjects: 175
Study 28346154 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention (2 text messages outlining individualized bedtime goals daily for 8 weekdays)
Number of subjects: 46
Study 28346154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message intervention)
Number of subjects: 46
Study 25724704 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (IC) protocol including multidisciplinary care coordination and patient case management
Number of subjects: 363
Study 25724704 — intervention group
Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 363
Study 23520977 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 eyes without macular pathology)
Number of subjects: 33
Study 23520977 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with CSME (21 eyes)
Number of subjects: 33
Study 20934897 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 700
Study 20934897 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG and HbA(1c) combination
Number of subjects: 700
Study 20934897 — intervention group
Group type: COMPARATOR
Intervention: FPG
Number of subjects: 700
Study 20934897 — intervention group
Group type: COMPARATOR
Intervention: 2hPG
Number of subjects: 700
Study 19345768 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic motor imagery of finger flexion movements during the postoperative dynamic splinting period
Number of subjects: 28
Study 19345768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motor imagery)
Number of subjects: 28
Study 19345768 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery group
Number of subjects: 28
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg day(-1)
Number of subjects: 48
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg day(-1)
Number of subjects: 48
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg day(-1)
Number of subjects: 48
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg day(-1)
Number of subjects: 48
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg day(-1)
Number of subjects: 48
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs tested (including aspirin)
Number of subjects: 48
Study 16689755 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups post-treatment
Number of subjects: 48
Study 15558071 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (33.3 mg m(‐2) for 6 weeks)
Number of subjects: 220
Study 15558071 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (75 mg m(‐2))
Number of subjects: 220
Study 15558071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both weekly and 3-weekly docetaxel
Number of subjects: 220
Study 11780943 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal rTMS (N = 16)
Number of subjects: 46
Study 11780943 — intervention group
Group type: EXPERIMENTAL
Intervention: Left prefrontal rTMS (N = 15)
Number of subjects: 46
Study 11780943 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (N = 15)
Number of subjects: 46
Study 9436162 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral strategies for managing auditory hallucinations
Number of subjects: 0
Study 9436162 — intervention group
Group type: EXPERIMENTAL
Intervention: Group practice of behavioral strategies
Number of subjects: 0
Study 8493629 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 388
Study 8493629 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (400 micrograms four times daily)
Number of subjects: 388
Study 8493629 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (400 micrograms twice daily)
Number of subjects: 388
Study 8493629 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol and Salbutamol
Number of subjects: 388
Study 30636064 — intervention group
Group type: EXPERIMENTAL
Intervention: Four implants in the posterior maxilla
Number of subjects: 66
Study 30636064 — intervention group
Group type: COMPARATOR
Intervention: Six implants in the posterior maxilla
Number of subjects: 66
Study 28560762 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 25 µg ODT + Tolterodine 4 mg (n=49)
Number of subjects: 106
Study 28560762 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 4 mg (n=57)
Number of subjects: 106
Study 28560762 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin + Tolterodine (n=49)
Number of subjects: 106
Study 28560762 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine (n=57)
Number of subjects: 106
Study 27596569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based secondary prevention program emphasizing early physical activity with a graduated walking program initiated on discharge from ACS admission.
Number of subjects: 0
Study 27596569 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based secondary prevention program
Number of subjects: 0
Study 25362163 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol administration
Number of subjects: 60
Study 25362163 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated RR series with metoprolol
Number of subjects: 60
Study 23043031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparrow-SES
Number of subjects: 36
Study 23043031 — intervention group
Group type: COMPARATOR
Intervention: Cypher-SES
Number of subjects: 36
Study 20449538 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg/day)
Number of subjects: 65
Study 20449538 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan (40 mg/day)
Number of subjects: 65
Study 18319519 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI (tenecteplase)
Number of subjects: 1090
Study 18319519 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1090
Study 18319519 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI
Number of subjects: 1090
Study 18319519 — intervention group
Group type: EXPERIMENTAL
Intervention: No baseline Q waves
Number of subjects: 1090
Study 16482400 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU wafers
Number of subjects: 240
Study 16482400 — intervention group
Group type: COMPARATOR
Intervention: Placebo wafers
Number of subjects: 240
Study 14738209 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs) (n = 30)
Number of subjects: 38
Study 14738209 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (n = 8)
Number of subjects: 38
Study 11123825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (400 microg/kg/body weight)
Number of subjects: 30
Study 11123825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethyl carbamazine (DEC) (6 mg/kg/body weight)
Number of subjects: 30
Study 9186324 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection alone or combined with intravesical bacillus Calmette‐Guerin
Number of subjects: 86
Study 9186324 — intervention group
Group type: COMPARATOR
Intervention: Control group (Transurethral resection alone)
Number of subjects: 86
Study 8259846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) 600 mg/day for 2 years
Number of subjects: 647
Study 8259846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) 600 mg/day plus Tamoxifen (TAM) 20 mg/day for 2 years
Number of subjects: 647
Study 8259846 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day for 2 years
Number of subjects: 647
Study 3964494 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate (1.5 g/day)
Number of subjects: 44
Study 3964494 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (50 IU X 5 days every third week)
Number of subjects: 44
Study 3964494 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Phosphate + Calcitonin)
Number of subjects: 44
Study 3964494 — intervention group
Group type: COMPARATOR
Intervention: Double placebos
Number of subjects: 44
Study 30848494 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 21
Study 30848494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29239867 — intervention group
Group type: EXPERIMENTAL
Intervention: AZI/AML/HCTZ 20/5/12.5 mg
Number of subjects: 353
Study 29239867 — intervention group
Group type: EXPERIMENTAL
Intervention: AZI/AML/HCTZ 20/5/6.25 mg
Number of subjects: 353
Study 29239867 — intervention group
Group type: EXPERIMENTAL
Intervention: AZI/AML 20/5 mg
Number of subjects: 353
Study 29239867 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 12.5 mg
Number of subjects: 353
Study 29239867 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 6.25 mg
Number of subjects: 353
Study 29239867 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measurement
Number of subjects: 353
Study 29239867 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 353
Study 27233494 — intervention group
Group type: EXPERIMENTAL
Intervention: PeriopSim™ Instrument Trainer
Number of subjects: 18
Study 27233494 — intervention group
Group type: EXPERIMENTAL
Intervention: PeriopSim™ for Burr Hole Surgery
Number of subjects: 18
Study 25549485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-doses of antithrombin III (AT)
Number of subjects: 29
Study 25549485 — intervention group
Group type: COMPARATOR
Intervention: No antithrombin III (AT)
Number of subjects: 29
Study 22470133 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary care model
Number of subjects: 189
Study 20099274 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on grief
Number of subjects: 182
Study 20099274 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on role transitions
Number of subjects: 182
Study 20099274 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on role disputes
Number of subjects: 182
Study 20099274 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on interpersonal deficits
Number of subjects: 182
Study 17275553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 75
Study 17275553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 75
Study 17275553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 1 mg iron/kg
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 2 mg iron/kg
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg at injection rates of 90 mg/min
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg at injection rates of 180 mg/min
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg at injection rates of 1800 mg/min
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 125 mg over 5 min in hemodialysis patients
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 250 mg over 5 min in hemodialysis patients
Number of subjects: 61
Study 16088081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol in both populations
Number of subjects: 61
Study 16088081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 12390947 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289
Study 12390947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study 11757538 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stones < or = 3 mm in diameter recovered in patients with ductal stones (n=22).
Number of subjects: 39
Study 11757538 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 patients) with normal antegrade SO activity.
Number of subjects: 39
Study 7749431 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol of gonadotropin releasing hormone agonist (GnRH‐a) administration
Number of subjects: 90
Study 7749431 — intervention group
Group type: COMPARATOR
Intervention: Short protocol of gonadotropin releasing hormone agonist (GnRH‐a) administration
Number of subjects: 90
Study 2108634 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study 2108634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 12
Study 2108634 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 12
Study 575498 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinol O-phosphate (COP) 3.06 g i.v./24 h for 3 days
Number of subjects: 46
Study 575498 — intervention group
Group type: COMPARATOR
Intervention: Glucose-insulin-K+ (GIK) for 3 days
Number of subjects: 46
Study 31484799 — intervention group
Group type: EXPERIMENTAL
Intervention: Selling tobacco
Number of subjects: 4527
Study 31484799 — intervention group
Group type: EXPERIMENTAL
Intervention: Formerly selling tobacco
Number of subjects: 4527
Study 31484799 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped selling tobacco
Number of subjects: 4527
Study 31484799 — intervention group
Group type: EXPERIMENTAL
Intervention: Might stop selling tobacco
Number of subjects: 4527
Study 31484799 — intervention group
Group type: EXPERIMENTAL
Intervention: Current sellers unlikely to stop selling
Number of subjects: 4527
Study 31484799 — intervention group
Group type: EXPERIMENTAL
Intervention: Former tobacco retailers in Western Australia
Number of subjects: 4527
Study 30856652 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 150
Study 30856652 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 150
Study 28303156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 21
Study 28303156 — intervention group
Group type: COMPARATOR
Intervention: Sham-TENS
Number of subjects: 21
Study 28303156 — intervention group
Group type: COMPARATOR
Intervention: Acu-TENS and Sham-TENS
Number of subjects: 21
Study 25556916 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin plus sorafenib (400 mg orally twice daily)
Number of subjects: 85
Study 25556916 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin
Number of subjects: 85
Study 25556916 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin plus sorafenib
Number of subjects: 85
Study 23363643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 12
Study 23363643 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 12
Study 20350786 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (NADT) for 0, 3, or 6 months prior to and during radiation treatment at 66 Gy
Number of subjects: 802
Study 20350786 — intervention group
Group type: COMPARATOR
Intervention: Radiation treatment alone
Number of subjects: 802
Study 20350786 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (NADT)
Number of subjects: 802
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening lipid profiles
Number of subjects: 5031
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate management within 4 months after screening
Number of subjects: 5031
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 5031
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol <or=130 mg/dL
Number of subjects: 5031
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 5031
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL levels between 131 and 159 mg/dL
Number of subjects: 5031
Study 19476583 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk category
Number of subjects: 5031
Study 17295586 — intervention group
Group type: EXPERIMENTAL
Intervention: Flatline cluster smoking patterns
Number of subjects: 351
Study 17295586 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dip-evening incline cluster smoking patterns
Number of subjects: 351
Study 17295586 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning high cluster smoking patterns
Number of subjects: 351
Study 17295586 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily decline cluster smoking patterns
Number of subjects: 351
Study 12891637 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting opioid therapy for 4 weeks
Number of subjects: 47
Study 12891637 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 47
Study 10861152 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 60
Study 10861152 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngeal mask airway (LMA)
Number of subjects: 60
Study 10861152 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) with introducer
Number of subjects: 60
Study 10861152 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) without introducer
Number of subjects: 60
Study 9198464 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclofenac 100 mg/12 h
Number of subjects: 30
Study 9198464 — intervention group
Group type: COMPARATOR
Intervention: paracetamol 650 mg/12 h
Number of subjects: 30
Study 1439622 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac + 200 micrograms misoprostol)
Number of subjects: 1501
Study 1439622 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg)
Number of subjects: 1501
Study 3084266 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 18
Study 3084266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 18
Study 3084266 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 18